Abu Dhabi’s Mubadala has reinvested in PCI Pharma Services, strengthening its healthcare portfolio with another strategic move. The company calls PCI one of its top-performing healthcare assets.
However, the new Mubadala healthcare investment is part of a larger deal co-led by Bain Capital and existing investor Kohlberg. The Partners Group also contributed with a minority investment, highlighting global confidence in PCI’s growth potential.
PCI Pharma Services specializes in contract manufacturing for biotherapies and has built a strong track record over 50 years. Mubadala first invested in PCI alongside Kohlberg several years ago. Since then, PCI has launched more than 450 products, demonstrating its capacity for innovation and consistent delivery.
Mubadala’s renewed interest in PCI underlines its commitment to healthcare investments that address global clinical needs. The company focuses on opportunities that help reduce healthcare costs and improve access for patients worldwide.
Camilla Languille, co-CEO of Private Equity at Mubadala, emphasized the success of their partnership with PCI’s management team. She highlighted how such collaborations drive growth, create value, and improve patient outcomes globally.
The sustained outsourcing of critical but non-core pharmaceutical activities continues to align with Mubadala’s strategy. This trend enables pharma companies to focus on innovation while relying on trusted partners like PCI for essential services.
This is Mubadala’s second major transaction in a short time, signaling an active approach to expanding its healthcare footprint. The company seeks to identify similar high-performing assets that complement its long-term vision.
With its robust financial strength, Mubadala Healthcare Investment aims to support companies like PCI in scaling operations and meeting rising demand in global biotherapy markets. This reinvestment strengthens Mubadala’s role as a leading player in the international healthcare investment arena.
The PCI deal reflects Mubadala’s strategy of targeting sectors with strong growth potential and societal impact. The company’s healthcare focus positions it as a key contributor to improving health systems worldwide.
